Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

RESPIRATORY SYNCYTIAL VIRUS (RSV) is a pneumovirus frequently associated with respiratory illnesses. 1-3 While RSV has been known to cause serious complications in infants and young children, it ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Adults can be at increased risk for RSV disease due to comorbidities, immune compromised status, or advanced age. 5 RSV can exacerbate conditions, including COPD, asthma, and chronic heart failure ...

For instance, in the 2014-20115 respiratory viral infection season, the number of RSV-related outpatient consultations for all age groups was 1,313,100, compared with 3,911,800 cases in the 2022 ...

Increases in COVID, RSV, and influenza are the result of governments refusal to enact public health measures and address ...

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...